- Home
- News Centre Resources
- Getting to Know Mary Kunjappu, an Alexion R&D Leading Voice
Getting to Know Mary Kunjappu, an Alexion R&D Leading Voice

Science is hard, but rare disease research and development (R&D) stands apart. Because individual patient populations are small and many rare diseases are not well understood, research in this space can often bring added complexity. Mary Kunjappu is a Medical Director in our Medical Affairs team in the US. We spoke with her about the importance of following the science, expecting the unexpected, and the endless possibilities in rare disease research.
How did you get involved in medical affairs?
I'm a bench scientist by training, and towards the end of my PhD, I got very interested in clinical research and the potential for things at the bench to have therapeutic effects. And after graduate school, I started working in medical communications because I was very passionate about talking about the science itself. I started working in rare diseases and I got the opportunity to come in-house with Alexion. I’ve been here for almost seven years now.

What led you to a job in rare disease, specifically?
[When] I started working in rare diseases, I really fell in love with the impact it can make and the work that we do for patients and families because many rare diseases are not well known, we get an opportunity to start educating healthcare providers and really, at the early stages, defining different aspects of the disease and what are the symptoms.
What about your work excites you?
I think it gets back to the impact we can make in rare disease where there is often nothing previously existing to help some of these patients, and we’re able to fill that gap. It’s a very unique position to be in.
What’s one lesson you’ve learned from working in rare disease R&D?
It’s all about following the science, even if it takes you to unexpected places. You need to be able to say, “this is where this is leading us, this is what we're learning about this, and the best way for us to understand this molecule,” and be open to making a change.
I’ve learned to really focus on what the information is, and what it is telling us, rather than having preconceived notions of where things should be, and really tailoring and figuring out what the next step should be.
Do you have any advice for someone considering a career in rare disease R&D?
There’re so many new things happening in science that if it doesn't exist today, it may exist tomorrow. Whatever different combination of interests you are thinking about is probably going to happen in the future. Don't limit yourself to what is possible today.
Learn more about our scientists, innovative culture, career opportunities at Alexion.
Share This Page
More articles you may like
Media [News] • April 10, 2025
Advancing Rare Disease Research Through Patient-Centric Trial Design
As Head of Development, Regulatory and Safety at Alexion, Gianluca Pirozzi channels his life’s experience with rare disease to inform his work at Alexion, ensuring clinical programmes are fueled by a patient-focused mindset.
Article • February 24, 2025
Supporting Patients on Rare Disease Day, and Every Day
Rare Disease Day recognizes the 400 million people worldwide – and 30 million in the United States – who are living with a rare disease. While significant progress has been made in understanding rare diseases and developing treatments, the need for continued awareness, research and support is as great as ever.
Patient Support • February 05, 2025
Addressing the Unmet Needs of the Amyloidosis Community
We spoke with Cristina Quarta, Executive Medical Director, about a group of rare diseases known as amyloidosis, the medical needs within this community and how her work as a cardiologist shapes her approach to research and development (R&D) for rare cardiac conditions.
Patient Support • September 23, 2024
Shortening the Path to Diagnosis in Rare Disease
With 10,000 known rare diseases defined today, the path to diagnosis can often resemble a puzzle, with physicians as detectives searching for clues. Many physicians never encounter a rare disease beyond the pages of their medical school textbooks.
Research and Development • September 18, 2024
Getting to know Nick France, an Alexion R&D Leading Voice
To create meaningful advances in rare disease research, it takes an innovative culture, strong collaboration, and a patient-centric vision for delivering transformational solutions. At Alexion, these pillars are important to successfully develop impactful medicines for patients.
Patient Support • June 25, 2024
Getting to know Chathuri Daluwatte, an Alexion R&D Leading Voice
Artificial Intelligence (AI) is rapidly advancing and has the potential to have a transformative impact on clinical research and development (R&D).
Research and Development • June 08, 2024
Getting to know Seng Cheng, an Alexion R&D Leading Voice
There is a sense of urgency that underlies research in rare diseases, because these diseases are often rapidly progressive.
Patient Support • April 18, 2024
Getting to know Sophia Zilber, Associate Director, Statistical Programming
The voices and perspectives of patients play an essential role in rare disease research and development (R&D).
Patient Support • April 16, 2024
Getting to know Banu Sankaran, an Alexion R&D Leading Voice
Diagnostics and artificial intelligence (AI) systems are transforming research and development (R&D) in the healthcare industry.
Health Equity • February 06, 2024
Driving health equity for the rare disease community
Collectively, more than 400 million people around the world are living with a rare disease, defined as conditions that affect a small number of people compared to the general population.